|
Acquisition of Assets (Details Textual) (USD $)
|
1 Months Ended |
|---|---|
|
Jan. 30, 2013
|
|
| Business Acquisition, Cost of Acquired Entity, Cash Paid | $ 500,000 |
|
Asset purchase agreement
|
|
| Business Acquisition, Cost of Acquired Entity, Cash Paid | 400,000 |
| Business Acquisition Purchases Price Allocation Assets Acquired | 100,000 |
|
Asset purchase agreement | Licensee
|
|
| Cumulative Sales Amount | 500,000,000 |
|
Asset purchase agreement | Maximum
|
|
| Business Acquisition Contingent Consideration At Fair Values | 44,000,000 |
|
Asset purchase agreement | Exclusive license of multi day injectable insulin in us
|
|
| Business Acquisition Contingent Consideration At Fair Values | 2,000,000 |
| Business Acquisition Contingent Consideration Amount Payment Period | 30 days |
| Business Combination, Contingent Consideration Arrangements, Description | Two million dollars ($2,000,000) to be paid within 30 days after the exclusive license of the multi-day injectable insulin in the United States to a commercial pharmaceutical company. |
|
Asset purchase agreement | Phase 2b Ccinical studies for multi day injectable insulin
|
|
| Business Acquisition Contingent Consideration At Fair Values | 2,000,000 |
| Business Acquisition Contingent Consideration Amount Payment Period | 30 days |
| Business Combination, Contingent Consideration Arrangements, Description | Two million dollars ($2,000,000) related to the initiation of Phase 2b clinical studies for a multi-day injectable insulin, payable 30 days after the first dosing of a patient in a formal Phase 2b clinical study; |
|
Asset purchase agreement | Phase 3 clinical studies for the multi-day injectable insulin
|
|
| Business Acquisition Contingent Consideration At Fair Values | 5,000,000 |
| Business Acquisition Contingent Consideration Amount Payment Period | 30 days |
| Business Combination, Contingent Consideration Arrangements, Description | Five million dollars ($5,000,000) after the initiation of Phase 3 clinical studies for the multi-day injectable insulin by the Company or a licensee of the Company, payable 30 days after the first dosing of a patient in a formal Phase 3 clinical study. |
|
Asset purchase agreement | Approval by fda or emea to allow marketing and sales of multi day injectable insulin
|
|
| Business Acquisition Contingent Consideration At Fair Values | 10,000,000 |
| Business Acquisition Contingent Consideration Amount Payment Period | 30 days |
| Business Combination, Contingent Consideration Arrangements, Description | Ten million dollars ($10,000,000) upon the approval by the FDA or EMEA to allow the marketing and sales of the multi-day injectable insulin by the Company or a licensee of the Company, payable 30 days after the receipt of the approval letter or notice from the FDA or EMEA. |
|
Asset purchase agreement | Twelve month cumulative sales of multi day injectable insulin
|
|
| Business Acquisition Contingent Consideration At Fair Values | $ 25,000,000 |
| Business Acquisition Contingent Consideration Amount Payment Period | 90 days |
| Business Combination, Contingent Consideration Arrangements, Description | Twenty five million dollars ($25,000,000) if the twelve month cumulative sales of the multi-day injectable insulin by the Company or a licensee of the Company reaches five hundred million dollars ($500,000,000) in any given twelve consecutive month period, so long as such period occurs during the life of the patents included in the purchased assets, payable 90 days after the twelfth month in which sales equaled or exceeded five hundred million dollars. |